NYSE: ABTAbbott Laboratories Stock
$123.97-2.18 (-1.73%)
Updated Nov 20, 2025
ABT Price
$123.97
Fair Value Price
N/A
Market Cap
$215.57B
52 Week Low
$110.86
52 Week High
$141.23
P/E
15.5x
P/B
4.21x
P/S
5.32x
PEG
N/A
Dividend Yield
1.43%
Revenue
$43.84B
Earnings
$13.98B
Gross Margin
55.9%
Operating Margin
19.72%
Profit Margin
31.9%
Debt to Equity
0.64
Operating Cash Flow
$9B
Beta
0.55
Next Earnings
Jan 21, 2026
Ex-Dividend
N/A
Next Dividend
N/A
ABT Overview
Abbott Laboratories is a medical device and health care company. Its products include various medical devices, diagnostic tools and technologies, branded generic medicines, and nutritional products. Among its well-known brands are Pedialyte, Similac, Ensure, Glucerna, ZonePerfect, FreeStyle Libre, i-STAT, and MitraClip. The company was founded in 1888 and is headquartered in Abbott Park, IL.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ABT's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
ABT
Ranked#46 of 107
Ranked#46 of 107
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $23.93 | A | |
| $10.29 | A | |
| $6.53 | A |
Be the first to know about important ABT news, forecast changes, insider trades & much more!
ABT News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ABT scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ABT is forecast by analysts to be unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ABT is good value based on its earnings relative to its share price (15.5x), compared to the US market average (42.99x)
P/E vs Market Valuation
ABT is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more ABT due diligence checks available for Premium users.
Valuation
ABT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
15.5x
Industry
25.48x
Market
42.99x
ABT is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
ABT is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
ABT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.21x
Industry
3.86x
ABT is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ABT's financial health
Profit margin
Revenue
$11.4B
Net Income
$1.6B
Profit Margin
14.5%
ABT's Earnings (EBIT) of $8.65B... subscribe to Premium to read more.
Interest Coverage Financials
ABT's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$84.2B
Liabilities
$32.9B
Debt to equity
0.64
ABT's short-term assets ($24.84B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ABT's short-term assets ($24.84B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ABT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ABT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$2.8B
Investing
-$457.0M
Financing
-$1.8B
ABT's operating cash flow ($9.12B)... subscribe to Premium to read more.
Debt Coverage Financials
ABT vs Medical Device Stocks
Abbott Laboratories Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.